Abstract
The emergence of resistance to former first-line antimalarial drugs has been an unmitigated disaster. In recent years, artemisinin class drugs have become standard and they are considered an essential tool for helping to eradicate the disease. However, their ability to reduce morbidity and mortality and to slow transmission requires the maintenance of effectiveness. Recently, an artemisinin delayed-clearance phenotype was described. This is believed to be the precursor to resistance and threatens local elimination and global eradication plans. Understanding how resistance emerges and spreads is important for developing strategies to contain its spread. Resistance is the result of two processes: (i) drug selection of resistant parasites; and (ii) the spread of resistance. In this review, we examine the factors that lead to both drug selection and the spread of resistance. We then examine strategies for controlling the spread of resistance, pointing out the complexities and deficiencies in predicting how resistance will spread.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 311-317 |
| Number of pages | 7 |
| Journal | International Journal of Antimicrobial Agents |
| Volume | 41 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 2013 |
Fingerprint
Keywords
- Artemisinin
- Drug resistance
- Malaria
- Plasmodium falciparum
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases
- Pharmacology (medical)
Cite this
Antimalarial drug resistance : A review of the biology and strategies to delay emergence and spread. / Klein, Eili.
In: International Journal of Antimicrobial Agents, Vol. 41, No. 4, 04.2013, p. 311-317.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Antimalarial drug resistance
T2 - A review of the biology and strategies to delay emergence and spread
AU - Klein, Eili
PY - 2013/4
Y1 - 2013/4
N2 - The emergence of resistance to former first-line antimalarial drugs has been an unmitigated disaster. In recent years, artemisinin class drugs have become standard and they are considered an essential tool for helping to eradicate the disease. However, their ability to reduce morbidity and mortality and to slow transmission requires the maintenance of effectiveness. Recently, an artemisinin delayed-clearance phenotype was described. This is believed to be the precursor to resistance and threatens local elimination and global eradication plans. Understanding how resistance emerges and spreads is important for developing strategies to contain its spread. Resistance is the result of two processes: (i) drug selection of resistant parasites; and (ii) the spread of resistance. In this review, we examine the factors that lead to both drug selection and the spread of resistance. We then examine strategies for controlling the spread of resistance, pointing out the complexities and deficiencies in predicting how resistance will spread.
AB - The emergence of resistance to former first-line antimalarial drugs has been an unmitigated disaster. In recent years, artemisinin class drugs have become standard and they are considered an essential tool for helping to eradicate the disease. However, their ability to reduce morbidity and mortality and to slow transmission requires the maintenance of effectiveness. Recently, an artemisinin delayed-clearance phenotype was described. This is believed to be the precursor to resistance and threatens local elimination and global eradication plans. Understanding how resistance emerges and spreads is important for developing strategies to contain its spread. Resistance is the result of two processes: (i) drug selection of resistant parasites; and (ii) the spread of resistance. In this review, we examine the factors that lead to both drug selection and the spread of resistance. We then examine strategies for controlling the spread of resistance, pointing out the complexities and deficiencies in predicting how resistance will spread.
KW - Artemisinin
KW - Drug resistance
KW - Malaria
KW - Plasmodium falciparum
UR - http://www.scopus.com/inward/record.url?scp=84875371577&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84875371577&partnerID=8YFLogxK
U2 - 10.1016/j.ijantimicag.2012.12.007
DO - 10.1016/j.ijantimicag.2012.12.007
M3 - Article
C2 - 23394809
AN - SCOPUS:84875371577
VL - 41
SP - 311
EP - 317
JO - International Journal of Antimicrobial Agents
JF - International Journal of Antimicrobial Agents
SN - 0924-8579
IS - 4
ER -